Ganga Pharmaceuticals (539680) H1 25/26 earnings summary

Executive summary

• Un-audited financial results for the half year ended September 30, 2025, were approved by the Board on November 7, 2025.

• Independent auditor's review found no material misstatements in the financial results.

Financial highlights

• Revenue from operations for the half year was ₹136.65 lakhs, up from ₹131.13 lakhs in the same period last year.

• Net profit for the half year was ₹2.48 lakhs, compared to ₹5.50 lakhs in the previous half year.

• Total income for the half year was ₹151.45 lakhs, with total expenses at ₹148.10 lakhs.

• Basic EPS for the half year was ₹0.04, down from ₹0.11 in the previous half year.

Outlook and guidance

• No deviation or variation in the utilization of proceeds from the warrant issue; funds are being deployed as planned.